Commercialization in Europe with selected partners
Positrigo plans to sell its novel technology in Europe by leveraging a network of established companies in selected countries. "Due to the fragmented healthcare system in Europe with different country specific purchase mechanisms and healthcare reimbursement systems, it is most efficient to partner with local companies in selected countries," explains Dr. Stefan Bircher, CCO at Positrigo. "This way we believe to achieve fast commercial traction and hope to be be able to offer best in class after sales support at the same time".
The NeuroLF system is the first device of its kind which received market clearance in Europe and in the US. These two market approvals are important milestones for commercial opportunities in other parts of the world.
About Positrigo:
Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Zurich, Switzerland, the medical device company was founded in 2018 as a spin-off of ETH Zurich. Positrigo's technology, development, clinical testing and commercialization has been supported by various private investors, the Swiss government and the European Innovation Council. NeuroLF – the company's first device – is an ultra-compact brain Positron Emission Tomography (PET) scanner which has applications in the assessment of causes of dementias, such as Alzheimer's disease and other brain related disorders. Learn more at http://www.positrigo.com.
Back to HCB News
